What is a cefoxitin screen on a sensitivity report?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

What is a Cefoxitin Screen on a Sensitivity Report?

A cefoxitin screen on a sensitivity report is a specialized test used to detect methicillin resistance (mecA or mecC-mediated resistance) in Staphylococcus species, serving as a more reliable alternative to oxacillin testing for identifying MRSA (methicillin-resistant Staphylococcus aureus) and methicillin-resistant coagulase-negative staphylococci.

Purpose and Clinical Significance

The cefoxitin screen test is specifically designed to detect the presence of the mecA gene (and less commonly mecC gene) that confers resistance to all beta-lactam antibiotics in staphylococci. This is critical because:

  • Cefoxitin is a potent inducer of the mecA regulatory system 1, making it more sensitive than oxacillin for detecting methicillin resistance
  • The test identifies organisms that produce altered penicillin-binding protein (PBP2a), which is the mechanism of methicillin resistance 2
  • It provides more reliable results than traditional oxacillin testing, particularly for heteroresistant strains that may be missed by oxacillin alone

How to Interpret the Results

Disk Diffusion Method

When you see a cefoxitin screen result on a sensitivity report:

  • Zone diameter ≤21 mm for S. aureus = Methicillin-resistant (MRSA) 3
  • Zone diameter ≤24 mm for coagulase-negative staphylococci = Methicillin-resistant 4
  • Zone diameter ≥22 mm for S. aureus = Methicillin-susceptible 3

Automated Systems

Modern automated susceptibility testing systems (Vitek 2, BD Phoenix) incorporate cefoxitin screen tests with high performance:

  • Vitek 2 cefoxitin screen: 100% sensitivity and 98% specificity when used alone 5
  • BD Phoenix cefoxitin screen: 84% sensitivity and 100% specificity when used alone, but reaches 100% sensitivity when combined with oxacillin testing 5

Performance Characteristics

The cefoxitin disk diffusion test demonstrates superior performance compared to oxacillin testing:

  • Sensitivity: 96.5-100% for detecting mecA-mediated resistance 3, 6, 2
  • Specificity: 99.1-100% 3, 6
  • No special test conditions required (unlike oxacillin testing which requires specific temperature and salt concentration) 3

Clinical Implications

When a cefoxitin screen is positive (resistant):

  • The organism should be considered resistant to ALL beta-lactam antibiotics (penicillins, cephalosporins, carbapenems) except ceftaroline and ceftobiprole
  • Treatment should shift to vancomycin, daptomycin, linezolid, or other non-beta-lactam agents
  • Infection control measures for MRSA should be implemented

When a cefoxitin screen is negative (susceptible):

  • The organism is methicillin-susceptible
  • Beta-lactam antibiotics remain appropriate treatment options based on other susceptibility results

Important Caveats

Do not confuse the cefoxitin screen with cefoxitin therapy: The cefoxitin screen is a diagnostic test for detecting methicillin resistance; it does NOT mean cefoxitin should be used for treatment of staphylococcal infections. Cefoxitin itself has limited activity against staphylococci and is primarily used for anaerobic and certain Gram-negative infections 7, 8.

For Enterobacterales: Cefoxitin screening has a completely different purpose—it can be used to screen for AmpC beta-lactamases, though it has poor specificity (25%) and should not be used as a stand-alone test for this purpose 9.

References

Research

Evaluation of a cefoxitin disk diffusion test for the routine detection of methicillin-resistant Staphylococcus aureus.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2004

Research

Cefoxitin for Intra-amniotic Infections and Endometritis: A Retrospective Comparison to Traditional Antimicrobial Therapy Regimens Within a Healthcare System.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2024

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.